GetWiki

{{Short description|Pharmaceutical drug}}{{Drugbox| Verifiedfields = changed| verifiedrevid = 477002950| IUPAC_name = Diphtheria toxin-Interleukin-2 fusion protein| image = | tradename = Ontak

monograph|denileukin_diftitox}}| MedlinePlus = a611024| pregnancy_AU = | pregnancy_US = C| pregnancy_category = | legal_AU = | legal_UK = | legal_US = Rx-only| legal_status = | routes_of_administration = Intravenous| bioavailability = | protein_bound = | metabolism = | elimination_half-life = 70-80 min| excretion =

correct|??}}| CAS_number = 173146-27-5| ATC_prefix = L01| ATC_suffix = XX29| ATC_supplemental = | PubChem = | IUPHAR_ligand = 7044

correct|drugbank}}| DrugBank = DB00004

changed|FDA}}| UNII = 25E79B5CTM

changed|EBI}}| ChEMBL = 1201550

changed|chemspider}}| ChemSpiderID = none

H=4042

O=799 | S=17}}Denileukin diftitox (trade name Ontak) was an antineoplastic agent, an engineered protein combining interleukin-2 and diphtheria toxin. Denileukin diftitox could bind to interleukin-2 receptorsJOURNAL, Turturro F, Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders, Expert Review of Anticancer Therapy, 7, 1, 11–7, January 2007, 17187516, 10.1586/14737140.7.1.11, 9028829, and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some leukemias and lymphomas, malignant cells express these receptors, so denileukin diftitox can target these. In 1999, Ontak was approved by the U.S. Food and Drug Administration (FDA) for treatment of Cutaneous T-cell lymphoma (CTCL).JOURNAL, Manoukian G, Hagemeister F, Denileukin diftitox: a novel immunotoxin, Expert Opinion on Biological Therapy, 9, 11, 1445–51, November 2009, 19817678, 10.1517/14712590903348135, 23956460, There is some evidence tying it to vision loss, and in 2006 the FDA added a black box warning to the drug's label.JOURNAL, Lansigan F, Stearns DM, Foss F, Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma, Cancer Management and Research, 2, 53–9, February 2010, 21188096, 3004568, 10.2147/cmar.s5009, free, In 2014, marketing of Ontak was discontinued in the US.WEB, FDA Drug Shortages,weblink U.S. Food and Drug Administration, 3 July 2017, 31 January 2014, References {{Reflist}} External links FDA Safety Alert {{Extracellular chemotherapeutic agents}}{{Interleukin receptor modulators}}{{antineoplastic-drug-stub}}